poisar

Economy · News reference

Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky

BenzingaChris Katje

A U.S. senator has added small cap stock ETFs to his portfolio ahead of a potential Federal Reserve rate hike. Here's why the timing matters.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    Following Goldman Sachs & UBS? Bet on S&P 500 ETFs for 2027

    Goldman Sachs and UBS project the S&P 500 will rise to 8,700-8,900 by 2027, supported by strong economic growth, attractive valuations following recent market corrections, and continued earnings growth despite expected slowdown. The U.S. economy expanded 3.4% in Q3 2026, and consumer sentiment improved, suggesting robust spending ahead. However, concerns remain over AI regulation, elevated inflation, and potential Fed hawkishness.

  2. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  3. Zacks Investment ResearchNa

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    The iShares U.S. Pharmaceuticals ETF (IHE) is reviewed as a reasonable option for investors seeking broad exposure to the Healthcare-Pharma sector. With $1.69 billion in assets and a 0.37% expense ratio, the fund has delivered strong year-to-date returns of 28.8% and one-year returns of 35.48%. However, it carries higher risk with a beta of 0.47 and standard deviation of 17.13%. Top holdings include Eli Lilly (26.88%), Johnson & Johnson, and Royalty Pharma, with the top 10 holdings representing 81.09% of assets.

  4. The Motley FoolKeith Speights

    If You Only Make 1 Investing Move Before 2027, History Says It Should Be This

    The article recommends investing in a low-cost S&P 500 index fund before 2027, citing three historical reasons: the third year of presidential cycles historically delivers the best returns, the S&P 500 has never had negative 20-year returns, and attempting to time the market is costly. Two recommended ETF options are highlighted as long-term investment vehicles.